Hexarelin (examorelin) has a plasma elimination half-life of approximately 70 minutes in human subjects, based on data from Laron et al. 1995 and Ghigo et al. 1994.[1,2] Also known as Examorelin and MF-6003, hexarelin is the most potent synthetic hexapeptide GHS-R1a agonist studied in humans — producing strong GH release alongside cortisol, ACTH, and prolactin co-elevation. Its unique CD36 receptor binding confers cardioprotective properties independent of the GH axis.
Hexarelin's elimination half-life in humans is approximately 70 minutes, with a reported range of 30–70 minutes depending on the study design and measurement methodology. The most frequently cited human data come from Laron et al. (1995) and Ghigo et al. (1994), both of which examined GH secretagogue kinetics in healthy adult volunteers.[1,2] This places hexarelin at a substantially shorter half-life than ipamorelin (~2 hours) and GHRP-6 (~2 hours), though its GH-releasing potency per unit dose is considerably higher.
Human pharmacokinetic characterization of hexarelin relied primarily on plasma immunoassay and radioimmunoassay methods in the mid-1990s. These studies measured both plasma hexarelin concentration decay (to establish the elimination t½) and the resulting GH secretory profile — allowing researchers to distinguish between the short plasma half-life and the longer duration of the biological GH response. The limited dataset reflects that hexarelin was never advanced to Phase III clinical development, so the PK evidence base remains smaller than for approved drugs.
A critical distinction for understanding hexarelin's pharmacology: plasma clearance and biological effect duration are not the same. While hexarelin is largely cleared from plasma within ~70 minutes (one half-life), the GH pulse it triggers lasts 3–4 hours post-injection. This dissociation occurs because GHS-R1a receptor activation initiates intracellular signaling cascades that persist after the ligand has been degraded. The receptor-level events — including IP3 pathway activation and voltage-gated calcium channel opening in somatotrophs — continue to drive GH secretion for hours after plasma hexarelin levels have become negligible.
Using the standard 5 half-life rule (time to 97% clearance), hexarelin is effectively eliminated from plasma in approximately 5.8 hours. The table below shows the estimated residual plasma concentration at each half-life interval following a single subcutaneous injection.
Hexarelin Plasma Clearance Timeline
| Time Post-Injection | Half-Lives Elapsed | % Remaining in Plasma | Context |
|---|---|---|---|
| 15–30 min | Tmax | Peak | Peak GH stimulus; peak plasma hexarelin |
| ~70 min | 1× | 50% | GH pulse still actively rising or at peak |
| ~140 min | 2× | 25% | GH pulse ongoing; plasma hexarelin declining |
| ~210 min | 3× | 12.5% | GH pulse ending; <13% plasma hexarelin remains |
| ~280 min | 4× | 6.25% | Essentially cleared; GH returning to baseline |
| ~350 min (~5.8 hr) | 5× | <3% | 97%+ clearance — next dose window appropriate |
Because hexarelin clears the plasma in under 6 hours, a single daily dose provides only a single GH pulse window. Most research protocols and clinical investigations have used 2–3 daily subcutaneous injections to create multiple GH pulses — an important consideration because physiological GH release is naturally pulsatile, and this pulsatility (rather than sustained GH elevation) appears critical for downstream IGF-1 effects and tissue remodeling outcomes.[2] Typical timing strategies target fasting states: upon waking, pre-workout, and the pre-sleep window to align with natural nocturnal GH surges.
Hexarelin is unique among commonly used GHRPs in that it causes progressive GH axis desensitization with prolonged continuous use — a phenomenon thoroughly documented by Arvat et al. (1997) and earlier investigators.[3] With daily multi-dose hexarelin administration, the GH response begins to diminish within 4–8 weeks and can become substantially blunted by weeks 12–16 of continuous use. This stands in marked contrast to ipamorelin, which does not appear to cause the same degree of receptor downregulation at standard doses.
GHRP Half-Life & Selectivity Comparison
| Compound | Half-Life | GH Potency | Cortisol / Prolactin Elevation | Desensitization |
|---|---|---|---|---|
| Hexarelin (Examorelin) | ~70 min | Very High | Significant | High (4–16 wk) |
| GHRP-2 | ~30 min | High | Moderate | Moderate |
| Ipamorelin | ~2 hours | Moderate | Minimal/None | Low |
| GHRP-6 | ~2 hours | Moderate–High | Moderate (ghrelin-like hunger) | Moderate |
Hexarelin is almost exclusively administered subcutaneously in research settings. Published pharmacokinetic data are limited, and no formal bioavailability comparisons between routes have been published in peer-reviewed literature for human subjects.
Hexarelin PK by Route
| Route | Half-Life | Tmax | Bioavailability | Data Source |
|---|---|---|---|---|
| Subcutaneous (SC) | ~70 min | 15–30 min | Estimated moderate | Laron et al. 1995; Ghigo et al. 1994 |
| Intravenous (IV) | ~30–55 min (preclinical) | Immediate | 100% (by definition) | Preclinical rodent data; limited human IV data |
| Intranasal | Not established | Not established | Not established | No published human PK data |
| Oral | Not applicable | Not applicable | Essentially zero (peptide) | Peptide; destroyed by GI proteolysis |
Hexarelin is not included in standard urine toxicology panels used for employment or clinical purposes. No widely published forensic detection threshold exists. In anti-doping sport contexts, the World Anti-Doping Agency (WADA) lists hexarelin as a prohibited GH secretagogue. Specialized laboratory LC-MS/MS methods have demonstrated the capacity to detect hexarelin in urine for approximately 4–6 hours post-injection, though this window is dose-dependent and can vary with hydration status, kidney function, and the specific detection methodology used. The peptide's short plasma half-life (~70 minutes) and rapid proteolytic degradation limit the practical detection window relative to longer-acting compounds.
Hexarelin is a synthetic hexapeptide: His-D-2-methylTrp-Ala-Trp-D-Phe-Lys-NH₂. Its short plasma half-life is primarily a consequence of rapid proteolytic degradation by circulating serine and cysteine proteases and peptidases present in plasma and tissue. The hexapeptide chain, while more protease-resistant than some endogenous peptides due to its D-amino acid substitutions, is still efficiently cleaved — particularly at the N-terminal and C-terminal regions. Hepatic and renal first-pass clearance also contribute to elimination. There is no evidence of significant enterohepatic recirculation for hexarelin.
After subcutaneous injection, hexarelin is absorbed into systemic circulation and rapidly distributes to hypothalamic and pituitary GHS-R1a receptors. Receptor occupancy at these sites triggers: (1) stimulation of GHRH release from hypothalamic neurons; (2) direct stimulation of pituitary somatotrophs via GHS-R1a-coupled phospholipase C/IP3 pathway; and (3) inhibition of somatostatin release. The combined effect produces a large, acute GH pulse. The intracellular signaling events initiated by receptor activation persist for 2–4 hours even as plasma hexarelin concentrations decline toward zero — explaining the dissociation between the 70-minute plasma t½ and the 3–4 hour GH pulse duration.[1]
One of hexarelin's most pharmacologically distinctive features is its binding to the CD36 scavenger receptor — a 88-kDa integral membrane glycoprotein expressed prominently in cardiac myocytes, macrophages, and endothelial cells. This interaction is entirely independent of GHS-R1a and does not require GH release to produce its effects. Muccioli et al. (2004) demonstrated that hexarelin-mediated CD36 activation in cardiac tissue triggers anti-apoptotic signaling, reduces ischemia-reperfusion injury, and attenuates post-infarct ventricular remodeling in animal models.[4]
The clinical significance of this finding lies in several implications: (1) hexarelin's cardiac effects are not simply a downstream consequence of its GH-releasing activity; (2) CD36-mediated cardioprotection may persist beyond plasma clearance, as receptor-level changes in cardiac tissue operate on different timescales than plasma drug levels; and (3) even in states of GHS-R1a desensitization (where GH response is blunted), the CD36 pathway may remain functional. This has led to interest in hexarelin analogs that selectively target CD36 without the GHS-R1a-associated side effects of cortisol and prolactin elevation.
Real-time concentration curves based on your actual dose and injection time. Visualize each GH pulse window, track dose overlaps, and rotate injection sites — all on-device, no account required.
Download on App StoreCompare hexarelin's pharmacokinetics with other GH axis compounds in the Halflife database:
The Halflife app models your exact protocol — dose, timing, stacking — and shows your live GH pulse windows throughout the day. Free iOS app, no account required.
Download on App Store